Daiichi recently tipped (PDF) its oncology sales to top ¥900 billion ($6.3 billion) in its 2025 financial year. Enhertu is the bedrock of the forecast but Daiichi also expects datopotamab ...

A press release has landed Daiichi Sankyo in hot water in the U.K. Pharma’s self-regulatory body found Daiichi prejudiced patient safety by failing to reference a contraindication, leading it to ...

When Zymeworks and Daiichi Sankyo initially teamed up on bispecific antibodies in 2016, they kept the financial details under wraps. Now, the pair is entering a new license agreement that could ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

BASKING RIDGE, N.J. & RAHWAY, N.J., August 06, 2024--Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, have expanded their existing global co ...

Merck & Co Inc. (MRK) and Daiichi Sankyo on Thursday said that the companies have withdrawn their application to the U.S. Food and Drug Administration (FDA) seeking permission to commercialize ...

Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 Ameri... Contact Us. Contact Us.

Daiichi Sankyo Co. and partner AstraZeneca Plc shares fell the most in years after a study of their highly-anticipated lung cancer medicine raised questions about its safety and effectiveness.